Drug intelligence / Profile preview

HN01001

Development stage: Unknown
Lead developer: Hana Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

HN01001 is a small molecule potassium-competitive acid blocker (P-CAB) developed by Hana Pharm for the treatment of erosive esophagitis. As a P-CAB, HN01001 functions by inhibiting the gastric H+/K+-ATPase (the proton pump) in a reversible and potassium-competitive manner. Unlike traditional proton pump inhibitors (PPIs), which are prodrugs requiring acid activation and form covalent bonds with the pump, P-CABs provide a more rapid onset of action and sustained acid suppression that is independent of food intake or gastric pH. HN01001 is currently undergoing Phase 1 clinical evaluation to assess its safety, tolerability, and pharmacodynamic profile in healthy volunteers.

Other names: HN01001HN-01001HN 01001

Targets

ATP4A (Potassium–transporting ATPase alpha chain 1)

Beyond the preview

Go deeper on HN01001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HN01001.

Explore the full profile